INFI - Infinity Pharmaceuticals: Cash Position Boosted Multiple Readouts Over The Next Year
Shares of tiny oncology player Infinity Pharmaceuticals (INFI) have lost over 30% of their value since my June 2018 update highlighted intriguing signs of clinical activity for IPI-549, combined with nivolumab in indications not usually responsive to anti-PD-1 therapy. I also noted that well-known institutional investor Biotechnology Value Fund owned over 27% of shares outstanding, indicative of manager Mark Lampert's high conviction on upside prospects.
Presently, I became interested in revisiting this under-the-radar immunotherapy player after thumbing through slides from management's presentation at the JPMorgan Healthcare Conference, which made me aware of multiple